{"contentid": 488283, "importid": NaN, "name": "Zydus Cadila gets US FDA nod for Imbruvica generic", "introduction": "Indian drugmaker Zydus Cadila, part of Cadila Healthcare, has received final approval from the US Food and Drug Administration to market ibrutinib capsules, 70mg and 140mg, a generic of blockbuster cancer drug Imbruvica.", "content": "<p>Indian drugmaker Zydus Cadila, part of Cadila Healthcare (BOM: 532321), has received final approval from the US Food and Drug Administration to market ibrutinib capsules, 70mg and 140mg, a generic of blockbuster cancer drug Imbruvica.</p>\n<p>Ibrutinib belongs to a class of drugs known as kinase inhibitors and is used to treat certain cancers, such as mantle cell lymphoma or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and Waldenstrom's macroglobulinemia.</p>\n<p>The branded drug is marketed by Johnson &amp; Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV). Global Imbruvica net revenues were $5.314 billion in full-year 2020, an increase of 13.7%, with US net revenues of $4.305 billion and international profit sharing of around $1 billion.</p>\n<h2><strong>180 days of generic drug exclusivity</strong></h2>\n<p>According to the US FDA letter, Zydus was the first Abbreviated New Drug Applicant to submit a substantially complete ANDA with a paragraph IV certification for ibrutinib capsules, 70mg. Therefore, with this approval, Zydus is eligible for 180 days of generic drug exclusivity for ibrutinib in this dosage. For ibrutinib Capsules, 140mg, the company will have 180-days of shared generic drug exclusivity. The 70mg capsule has brand sales of $32.5 million, while the 140mg dose has brand sales of $745.9 million. Zydus is the first company to receive approval for generic ibrutinib 70mg capsules.</p>\n<p>Managing director of Zydus Group, Dr Sharvil Patel, commented: \"This FDA approval of Ibrutinib Capsules reinforces our long-term commitment to provide patients and caregivers access to affordable therapies. &nbsp;We have been investing significantly in building a portfolio of complex generic products and leveraging capabilities that will help us successfully commercialize and gain meaningful market share in the complex generic products and difficult-to-manufacture generic products. We have created a diversified portfolio of over 50 filed complex ANDAs seeking US FDA approval and we will continue to expand this as we explore opportunities to grow our US business in 2021 and beyond.&rdquo;</p>\n<p>The drug will be manufactured at the group&rsquo;s formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 313 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in fiscal year 2003-04.</p>", "date": "2021-04-08 11:19:00", "meta_title": "Zydus Cadila gets US FDA nod for Imbruvica generic", "meta_keywords": "Zydus Cadila, ibrutinib, FDA, Approval, Imbruvica, AbbVie, Johnson & Johnson", "meta_description": "Zydus Cadila gets US FDA nod for Imbruvica generic", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-08 11:17:53", "updated": "2021-04-08 11:26:33", "access": NaN, "url": "https://www.thepharmaletter.com/article/zydus-cadila-gets-us-fda-nod-for-imbruvica-generic", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "zyduscadilabig.jpg", "image2id": "zyduscadilasmall.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Generics", "therapy area_tag": "Hematology, Oncology", "topic_tag": "Focus On, Regulation, US FDA", "geography_tag": "India, USA", "company_tag": "AbbVie, Johnson & Johnson, Zydus Cadila", "drug_tag": "ibrutinib, Imbruvica", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-08 11:19:00"}